0001567619-20-018012.txt : 20201020
0001567619-20-018012.hdr.sgml : 20201020
20201020170009
ACCESSION NUMBER: 0001567619-20-018012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201020
FILED AS OF DATE: 20201020
DATE AS OF CHANGE: 20201020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Woiwode Thomas
CENTRAL INDEX KEY: 0001619294
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 201248813
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2020-10-20
0
0001799448
Aligos Therapeutics, Inc.
ALGS
0001619294
Woiwode Thomas
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2020-10-20
4
C
0
2145991
A
2145991
I
See footnote
Common Stock
2020-10-20
4
C
0
198839
A
2344830
I
See footnote
Common Stock
2020-10-20
4
C
0
85065
A
2429895
I
See footnote
Common Stock
2020-10-20
4
C
0
463959
A
463959
I
See footnote
Common Stock
2020-10-20
4
C
0
198485
A
662444
I
See footnote
Common Stock
2020-10-20
4
P
0
200000
15
A
862444
I
See footnote
Series A Preferred Stock
2020-10-20
4
C
0
2145991
0.00
D
Common Stock
2145991
0
I
See Footnote
Series B-1 Preferred Stock
2020-10-20
4
C
0
198839
0.00
D
Common Stock
198839
0
I
See Footnote
Series B-1 Preferred Stock
2020-10-20
4
C
0
463959
0.00
D
Common Stock
463959
0
I
See Footnote
Series B-2 Preferred Stock
2020-10-20
4
C
0
85065
0.00
D
Common Stock
85065
0
I
See Footnote
Series B-2 Preferred Stock
2020-10-20
4
C
0
198485
0.00
D
Common Stock
198485
0
I
See Footnote
Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
These securities are held of record by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
/s/ Lucinda Y. Quan, as attorney-in fact for Thomas Woiwode
2020-10-20